CN101874809A - Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent - Google Patents
Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent Download PDFInfo
- Publication number
- CN101874809A CN101874809A CN2010101489479A CN201010148947A CN101874809A CN 101874809 A CN101874809 A CN 101874809A CN 2010101489479 A CN2010101489479 A CN 2010101489479A CN 201010148947 A CN201010148947 A CN 201010148947A CN 101874809 A CN101874809 A CN 101874809A
- Authority
- CN
- China
- Prior art keywords
- glycerol
- mixed solvent
- dmso
- inflammatory
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 title claims abstract description 250
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title claims abstract description 215
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 58
- 239000012046 mixed solvent Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 17
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 9
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 5
- 235000006226 Areca catechu Nutrition 0.000 claims description 5
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 5
- 244000061520 Angelica archangelica Species 0.000 claims description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 241000951473 Schizonepeta Species 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims 2
- 244000080767 Areca catechu Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
- 208000025865 Ulcer Diseases 0.000 abstract description 23
- 231100000397 ulcer Toxicity 0.000 abstract description 23
- 230000006378 damage Effects 0.000 abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 abstract description 12
- 230000003628 erosive effect Effects 0.000 abstract description 12
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 230000001684 chronic effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 2
- 229940037003 alum Drugs 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 description 49
- 230000004054 inflammatory process Effects 0.000 description 34
- 206010061218 Inflammation Diseases 0.000 description 31
- 230000000694 effects Effects 0.000 description 31
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 26
- 206010030113 Oedema Diseases 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 230000007170 pathology Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 206010020880 Hypertrophy Diseases 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- RQIPBIVCBNQPDN-UHFFFAOYSA-N methylsulfinylmethane;propane-1,2,3-triol Chemical compound CS(C)=O.OCC(O)CO RQIPBIVCBNQPDN-UHFFFAOYSA-N 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 206010053615 Thermal burn Diseases 0.000 description 8
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 208000002894 beriberi Diseases 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 6
- 238000006297 dehydration reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000003722 extracellular fluid Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 6
- 239000003270 steroid hormone Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010046914 Vaginal infection Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002085 irritant Substances 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 244000235603 Acacia catechu Species 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 208000007514 Herpes zoster Diseases 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 230000007950 acidosis Effects 0.000 description 4
- 208000026545 acidosis disease Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000007117 Oral Ulcer Diseases 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 231100000460 acute oral toxicity Toxicity 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 206010008323 cervicitis Diseases 0.000 description 3
- 201000003988 chronic cervicitis Diseases 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000034493 Mucous membrane disease Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000003505 cervical polyp Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- -1 tincture Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 201000006994 chronic ulcer of skin Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WRWRKDRWMURIBI-UHFFFAOYSA-M mercuric amidochloride Chemical class N[Hg]Cl WRWRKDRWMURIBI-UHFFFAOYSA-M 0.000 description 1
- 229960000432 mercuric amidochloride Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a local anti-inflammatory external medicinal composition using a glycerol DMSO mixed solvent, which comprises alum, a medicament with anti-inflammatory effective dose, and a mixed solvent which is used for dissolving the alum and the medicament and consists of dimethyl sulfoxide and glycerol in a volume ratio of 1:0.5-5. The external medicinal composition is a new dimethyl sulfoxide and glycerol external anti-inflammatory medicament, is used for treating various refractory and inflammatory mucocutaneous diseases, has the local anti-inflammatory effect by inhibiting inflammatory, and promotes injuries such as local blister, erosion, effusion, herpes and chronic ulcers to quickly heal.
Description
Technical field
The present invention relates to medical technical field and population health technical field, relate to a kind of local anti-inflammatory external medicinal composition that uses glycerol DMSO mixed solvent particularly.
Background technology
Inflammation is a kind of defensive protection's reaction that body fights back the disease; help rehabilitation; but inflammation has dual nature; promptly in the autoprotection course of reaction; usually cause autologous tissue's damage; cause that disease increases the weight of, damage that the inflammation local response causes such as blister, ulcer, hypertrophy etc. lack ideal medicine at present.Inflammation can cause that the pathomechanism of inflammation local damage and evolution can be summarized as follows by multiple reasons such as pathogenic microorganism, chemical factors, allergy, immunoreation: inflammation pathology comprises that cell goes bad (cellular edema, degeneration, necrosis), oozes out, three kinds of pathological changes of hypertrophy.Evolution is: early stage because vasodilation causes oozes out and soaks into, and oozes out to cause the interstitial fluid increase to cause tissue edema, and clinical manifestation is local red and swollen; Cellular edema causes cytopathy, necrosis; Along with the lesion development interstitial fluid too much forms blister, epidermis cell causes the erosion of skin ulceration because of anoxia, acidosis death come off; Recover the stage in the later stage, tissue repair forms cicatrix, wound healing.If in inflammatory process the infringement factor and defense mechanism both sides to struggle against strength suitable, then inflammation will enter chronic phase, show as chronic inflammatory hypertrophy such as polyp, struvite granuloma etc.Cellular edema and tissue edema are the beginnings of inflammation Histological injury, after inflammation is brought out, at first ooze out and edema, and cause cell hypoxia and dysbolismus thus, cause cytopathy, necrosis.Edema, ooze out, cell hypoxia is the result of acute inflammation local response, it also is the immediate cause of pathological development, they influence each other, reciprocal causation, therefore, if can in disease process, control cellular edema and tissue edema, inhibition are oozed out, can prevent that then damage from increasing the weight of, and avoids generations such as blister, herpes, ulcer.
Dosage form is the indispensable form of drug use, drug solution type preparation is meant that medicine is dispersed in the liquid preparation that forms in the solvent with molecule or ionic condition, conventional dosage forms such as existing external used medicine solution type preparation such as lotion, tincture, oil preparation mainly are that water, ethanol or vegetable oil are as solvent.But there is following shortcoming in above-mentioned conventional dosage forms: aqueous pharmaceutical is easily muddy, form floccule or precipitation easily, easily go mouldy; Tincture has intense stimulus, volatile or precipitation; Oil preparation and water are insoluble, and is greasy, is unfavorable for the wound surface drying, and its hydration can cause palor to expand, and hinders wound healing.
Summary of the invention
The invention provides a kind of local anti-inflammatory external medicinal composition that uses glycerol DMSO mixed solvent, to solve the above-mentioned problems in the prior art.It is the mixed solvent that 1: 0.5～5 DMSO and glycerol are formed that externally-applied medicinal composition provided by the invention uses by volume ratio, obtains novel dimethyl sulfoxide glycerin, from pharmaceutical technology overcome existing Chinese medicine easy muddiness, shortcoming such as easily precipitate, easily go mouldy.Externally-applied medicinal composition provided by the invention is brought into play antiinflammatory action by picking up anti-inflammatory pathology new mechanism, but the amelioration of inflammation local response prevents the cell injury development and impels pathological changes such as blister, erosion, ulcer to heal rapidly.
The technical solution used in the present invention is as follows:
The local anti-inflammatory external medicinal composition of a kind of use glycerol DMSO (dimethyl sulfoxide) mixed solvent is characterized in that: what comprise the medicine of Alumen, anti-inflammatory effective amount and be used to dissolve Alumen and described medicine is the mixed solvent that 1: 0.5～5 dimethyl sulfoxide and glycerol are formed by volume ratio.
As the glycerol stable in properties of one of solvent, the zest of energy cushion, molecular weight is little freely to enter in the cell membrane its hydroxyl energy and H
2O forms hydrogen bond and closes with water dungeon is fixed, and skin mucosa is had dehydration, and makes local organization softening, and is bigger than ethanol to the inorganic salt dissolubility, participates in metabolism and can make oxidative phosphorylation coupling again, so can alleviate cell injury; The viscosity of glycerol is big and chemism is less, and antisepsis is arranged, and prevents drying, skin care, the local curative effect effect of prolong drug.Another solvent DMSO has the title of " alembroth ", soluble end is extensive, can with water and immiscible organic solvent, form the hydrogen chain with water, but can combine with the ion and the neutral molecule of polarity or polar, therefore be the good solvent of Organic substance and inorganic matter, can replace in the horny layer moisture extracts with lipid simultaneously and changes the protein configuration effect, some insoluble drugs also are dissolved among the DMSO, DMSO is a kind of widely used transdermal absorption accelerator, have strong absorptive simultaneously, antiinflammatory is arranged, local anaesthesia, antibacterial, pain relieving, blood vessel dilating, promote the wound healing effect, DMSO is applicable to chronic, the hypertrophy damage.
Glycerol and DMSO are used in combination, and can guarantee to dissolve the extraction effect and the quality of the pharmaceutical preparations, and keep the two effect and function.Because the character of DMSO and glycerol is all very stable, so this pharmaceutical composition has overcome easily muddy, the shortcoming such as precipitate, go mouldy of existing solution, good stability.
The Alumen that uses as the present invention has broad-spectrum antibacterial action, can absorb moisture from cell and make the cell dehydration condensation, reduces the inflammation exudate; Solidifiable protein is combined into the proteinate precipitation that is insoluble in water with serum albumin, makes and organizes wound surface to present drying, thereby stronger convergence exsiccation is arranged.These effects have extremely strong specific aim to inflammation pathology, can be by the damage mechanism treatment inflammation local patholoic change that controls inflammation.
These three kinds of material use in conjunction of Alumen, glycerol and DMSO have synergism, significantly promote the local anti-inflammatory therapeutic effect of externally-applied medicinal composition, are listed below:
1, broad-spectrum antibacterial action;
2, powerful water sorption and astriction absorb moisture, eliminate cellular edema and tissue edema, impel the cell dehydration condensation; The absorptive tissue interstitial fluid suppresses to ooze out, and prevents that blister from forming; Protein in the precipitation transudate, convergence protection wound surface;
3, antiinflammatory action is picked up anti-inflammatory pathology effectively, eliminates edema, improves local partial pressure of oxygen, shortens cell oxygen supply distance, helps oxygen supply, increases cell to anoxybiotic tolerance, prevents that damage from taking place or development increases the weight of to cause necrocytosis, thereby avoids ulcer to take place; Impel inflammation to disappear, improve the parabiosis organizational vitality, promote to repair; Suppress hypertrophy.
Pharmaceutical composition of the present invention has powerful local anti-inflammatory effect, but inflammation-inhibiting pathology, its anti-inflammatory mechanisms is different with existing external 4 classes " antiinflammatory " (tar class, ichthyol, ammoniated mercury, steroid hormone class) action principle, and Fig. 1 has shown the mechanism of action comparative result of this pharmaceutical composition and the most frequently used steroid hormone AID; Also carried out the comparison that the most frequently used steroid hormone AID and this pharmaceutical composition act on the different phase of inflammation damnification process simultaneously, the result as shown in Figure 2: 1,2,3,4 represent the steroid hormone site of action; A, B, C, D represent the site of action of pharmaceutical composition of the present invention, wherein, suppress to cause scorching meson 1, reduce vascular permeability, reduce and ooze out and infiltration 2, suppress connective tissue proliferation 3 and resisting mitosis 4; Absorb moisture and reduce interstitial fluid, make cell dehydration, alleviate cellular edema, degeneration, prevent cell death A, suppress to ooze out, improve oxygen supply, recovery parabiosis organizational vitality, promote to repair B, convergence granulation promoting C and the chronic hypertrophy D of inhibition.
As can be seen, hormone mainly acts on the inflammatory process first half from Fig. 1 and Fig. 2, to the basic not effects such as ulcer blister that taken place, forbids clinically in this type of infectious damage (practical dermatological/Liu assists core 2005:102).Pharmaceutical composition of the present invention is then opposite, act on the inflammatory process latter half, can be in edema, ooze out, control pathological development on the key link of tissue injury such as cell hypoxia, blister, erosion, the ulcer that can impel inflammation to cause heal rapidly, thereby new local anti-inflammatory approach is provided, has solved by drug effect and prevented that the inflammation local damage from taking place or the important technology problem of development.Therefore, from pharmacological action and clinical use angle, this pharmaceutical composition is a kind of novel mechanism of action " the local antiinflammatory of Chinese medicine " that has.
Inflammatory skin mucous membrane disease sickness rate is high, account for the dermopathic overwhelming majority, as shown in Fig. 3, Fig. 4, because inflammatory skin mucous membrane disease local damage pathology is basic identical, so this pharmaceutical composition is specially adapted to the treatment of the various diseases shown in the table 1:
Table 1 disease and the cause of disease thereof, pathology and symptom
In the local anti-inflammatory external medicinal composition of aforementioned use glycerol DMSO mixed solvent, preferably using volume ratio is 1: 4 the dimethyl sulfoxide and the mixed solvent of glycerol composition.
In the local anti-inflammatory external medicinal composition of aforementioned use glycerol DMSO mixed solvent, the w/v of Alumen and glycerol/DMSO mixed solvent is 1～10g/100ml, is preferably 5g/100ml.
In the local anti-inflammatory external medicinal composition of aforementioned use glycerol DMSO mixed solvent, described medicine is that weight ratio is the DMSO extract and the Borneolum Syntheticum of 1: 0.5～1.5: 0.1～0.3 Cortex Phellodendri, Radix Sophorae Flavescentis, catechu, the w/v of employed Cortex Phellodendri medical material or Radix Sophorae Flavescentis medical material and glycerol/DMSO mixed solvent is 5g/1000ml～15g/1000ml, and the w/v of Borneolum Syntheticum and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
Cortex Phellodendri, Radix Sophorae Flavescentis, catechu and Alumen compatibility have strong inhibitory action to gram-positive bacterium, gram negative bacteria, mycete and infusorian; Borneolum Syntheticum has antiinflammatory action, rat Ovum Gallus domesticus album pedal swelling there is remarkable inhibitory action, and dimethyl sulfoxide glycerol mixed solvent has powerful dissolving extraction effect, have antibacterial, antiinflammatory, the exsiccation that absorbs water by force simultaneously concurrently, and promote that effective ingredient enters intralesional, the antimicrobial antiphlogistic effect is strengthened; Above-mentioned effect is collaborative mutually, can control inflammation effectively, correct cell hypoxia and acidosis, prevent that inflammation damnification from further aggravating, create normal interior environment, make cell recover the normal physiological state as early as possible, avoid the continuous death of cell to come off, thereby create essential condition for rehabilitation, promote the inflammation damnification healing.Evidence, this externally-applied medicinal composition has significant effect to vaginitis, cervical erosion, can be used for the treatment of vaginitis and cervical erosion.
In the local anti-inflammatory external medicinal composition of aforementioned use glycerol DMSO mixed solvent, described medicine is the DMSO extract and the Borneolum Syntheticum of Indigo Naturalis, the w/v of employed Indigo Naturalis medical material and glycerol/DMSO mixed solvent is 5g/1000ml～15g/1000ml, and the w/v of Borneolum Syntheticum and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
In the local anti-inflammatory external medicinal composition of aforementioned use glycerol DMSO mixed solvent, described medicine is that weight ratio is the DMSO extract of 1: 1～2 Herba Schizonepetaes and the Radix Angelicae Dahuricae, and the w/v of employed angelica root and glycerol/DMSO mixed solvent is 10g/1000ml～20g/1000ml.
In the local anti-inflammatory external medicinal composition of aforementioned use glycerol DMSO mixed solvent, described medicine is that weight ratio is 1: 1～2 the Cortex Phellodendri and the DMSO extract and the Borneolum Syntheticum of Rhizoma Polygoni Cuspidati, the w/v of employed Rhizoma Polygoni Cuspidati medical material and glycerol/DMSO mixed solvent is 10g/1000ml～20g/1000ml, and the w/v of Borneolum Syntheticum and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
In the local anti-inflammatory external medicinal composition of aforementioned use glycerol DMSO mixed solvent, described medicine is a hibitane, and the w/v of hibitane and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
This preparation of drug combination method that provides among the present invention is as follows:
The ingredient of treatment effective dose is dissolved in the dimethyl sulfoxide or use dimethylsulfoxide extraction, and acquisition contains the dimethyl sulphoxide solution of ingredient; Then Alumen is dissolved in the glycerol, obtains the glycerite of Alumen; Above-mentioned two parts solution is mixed, obtain this pharmaceutical composition.
From production technology, pharmaceutical composition of the present invention is made up of two kinds " intermediate liquids ", and a kind of is that Alumen glycerite (Alumen Glycerine solution) is called for short AG liquid; Another kind is dimethylsulfoxide extraction liquid (Dimethylsulfoxide extract solution) vehicle economy liquid, so pharmaceutical composition of the present invention can be called for short " AGDE compositions " or " AGDE preparation ".
Pharmaceutical composition of the present invention constitutes the local anti-inflammatory pharmaceutical composition that " antiinflammatory platform " carries different pharmaceutical by Alumen, glycerol, dimethyl sulfoxide, be particularly suited for carrying the medicine that some special pathogen such as suppuration bacterium, fungus, bacillus pyocyaneus, virus etc. is had special killing action, make it to be suitable for more some special treatment of conditions, select for use different prescriptions can obtain different AGDE preparation new drugs, AGDE preparation new drug is a kind of novel dimethyl sulfoxide glycerin local anti-inflammatory new drug.
Unless name especially, the common implication of understanding of one technical staff of implication and the technical field of the invention of employed here all technology and scientific terminology is identical.Equally, all publication, patent application, patent and other reference materials all can be introduced the present invention as a reference referred in this.
The feature of pharmaceutical composition of the present invention is that the effect of Alumen, glycerol, dimethyl sulfoxide is added among the effect of " prescription compatibility of medicines ", " prescription effect " becomed privileged, so pharmaceutical composition of the present invention has following important feature:
1, to use by volume ratio be the mixed solvent that 1: 0.5～5 DMSO and glycerol are formed for externally-applied medicinal composition provided by the invention, obtain novel dimethyl sulfoxide glycerin, overcome the easy muddiness of existing Chinese medicine, easily precipitation, easy shortcoming such as go mouldy from pharmaceutical technology; And provide powerful local anti-inflammatory effect jointly by the Alumen that is dissolved in the glycerol DMSO mixed solvent; Then by in above-mentioned solution, adding different anti-inflammatory drugs, produce different external new drugs, therefore, externally-applied medicinal composition of the present invention constitutes the novel dimethyl sulfoxide glycerin local anti-inflammatory new drug that " antiinflammatory platform " carries other different pharmaceuticals by Alumen, glycerol, DMSO, is used for the treatment of different inflammatory skin membrane diseases;
2, quality height, stable in properties, clean appearance clear and bright, no muddy, do not have precipitation, no floccule, a nonirritant;
3, pharmaceutical composition of the present invention has Transdermal absorption promotion performance, and can prevent incrustation to form, and avoids infecting under the crust;
4, the local anti-inflammatory effect is strong, has inflammation-inhibiting pathology, eliminate cellular edema and tissue edema, inhibition is oozed out, reduce interstitial fluid and improve local partial pressure of oxygen, shorten oxygen supply, correct acidosis apart from increasing the cell oxygen supply, improve the cell hypoxia tolerance, prevent the local damage development and promote blister, ooze out, inflammatory lesions such as erosion and ulcer heal rapidly;
5, suppress the chronic inflammatory hypertrophy, prevent that granulation tissue from forming, can make polyp (as cervical polyp) complete obiteration or dwindle;
6, have hydrophilic and lipotropy double properties concurrently, help medicine and enter in the skin focus, (characteristic of skin texture has determined lipophilic drugs to be not easy by each layer below the horny layer by horny layer easily to improve drug utilization degree and therapeutic effect; Hydrophilic medicament then is not easy by horny layer but easily by each layer below the horny layer (percutaneous dosing novel form/Zheng Jun people 2006:18)).
Description of drawings
Fig. 1 is the sketch map of steroid hormone AID commonly used with the different mechanism of action of this pharmaceutical composition;
Fig. 2 acts on the sketch map of the different phase of inflammation damnification process for steroid hormone AID commonly used and this pharmaceutical composition;
Fig. 3 is the generation of chronic cervicitis and controls rotten spirit oil and treat principle schematic;
Fig. 4 is inflammation damnification process and ulcer oil treatment principle schematic.
The specific embodiment
Can further understand the present invention by the embodiment of the invention given below, but protection scope of the present invention is not limited thereto.
Embodiment 1
Dimethyl sulfoxide glycerite (DMSO working concentration 50%)
Preparation method: measure glycerol 500ml, DMSO500ml mixes two kinds of materials, stir, and makes 1000ml dimethyl sulfoxide glycerite.
DMSO is first Percutaneous absorption enhancer that is widely used after 20th century 60, multiple pharmacological effect is arranged, can improve the rat pedal edema that carrageenin causes, inhibition is with the arthritis of fungal infection, the arthritis that inhibition causes with 6-sulfanilamidazolez (percutaneous dosing novel form/Zheng Jun people 2006:42,84), clinically be used for the treatment of matter inflammation between some refractory disease such as bladder, scleroderma, the persistency herpes zoster, serious symptom rheumatoid arthritis, and herpes simplex, acute eczema is particularly red and swollen obviously or the eczema of volume transudate .2007:138 such as () dermatopathy and venereal disease Drug therapy guide/Hu Xiaojun.At present, directly treating disease with DMSO mainly is to use with the aqueous solution form, and dimethyl sulfoxide and glycerol can be miscible with any ratio, can keep separately character and pharmacological action after miscible, and the powerful absorption water function of collaborative composition.Curative effect of medication depends mainly on medicine itself, but under certain condition, dosage form also can play key effect to the performance of curative effect of medication, tend to make stability of drug, onset time, action intensity, persistent period, side effect etc. bigger difference to occur, even change drug effect (flow process pharmacy of Chinese materia medica/dragon English .2006:10 dawn).Glycerol in the dimethyl sulfoxide glycerite can be alleviated the zest of DMSO, and preparation is sticky, tack good, suction removes moist by force, so the dimethyl sulfoxide glycerite is to use the good method of DMSO, and working concentration can be adjusted as required.
Embodiment 2
Alumen dimethyl sulfoxide glycerol
Prescription: Alumen 50 grams (Alumen working concentration 5 gram/100ml manufacture Alumen dimethyl sulfoxide glycerol 1000ml).
Preparation method:
The first step: preparation Alumen glycerite,
1, calculate: the Alumen working concentration is 5g/100ml, and the volume ratio of glycerol and DMSO is 4: 1, and then the concentration of Alumen preparation liquid is 6.25g/100ml;
2, take by weighing Alumen 62.5 grams, measure glycerol 1000ml; Alumen is dissolved in the glycerol, promptly gets the preparation liquid of 6.25g/100ml, standby;
Second step: preparation: measure 6.25g/100ml Alumen glycerite 800ml, add DMSO200ml, stir, make Alumen dimethyl sulfoxide glycerol 1000ml.
Alumen character is special, and its chemical constituent is an aqueous sulfuric acid aluminum potassium, but coagulated particles purify waste water, medicinally seldom make aqueous solution with other drug matchings, how to use as astringent with the dried Alumen form.The compositions of Alumen, glycerol and three kinds of materials of dimethyl sulfoxide, can be their distinctive physicochemical properties and pharmacological action common powerful local anti-inflammatory effect and the convergence exsiccation of forming that be grouped together, can be effectively to anti-inflammatory pathology, on the key link of tissue injury, bring into play antiinflammatory action, cell injury takes place or development when preventing inflammation, impel local inflammation to disappear, promote that the inflammation that has taken place is oozed out, rotten to the corn, ulcer sexually transmitted disease (STD) change healing rapidly, Alumen dimethyl sulfoxide glycerite has following effect:
1, broad-spectrum antibacterial action;
2, powerful water sorption and astriction absorb moisture, eliminate cellular edema and tissue edema, make the cell dehydration condensation; The absorptive tissue interstitial fluid suppresses to ooze out, and prevents that blister from forming; Protein in the precipitation transudate, convergence protection wound surface prevents that incrustation from forming;
3, antiinflammatory action is picked up anti-inflammatory pathology effectively, eliminates edema, improves local partial pressure of oxygen, shorten cell oxygen supply distance, help oxygen supply, increase cell anoxybiotic tolerance, prevent that inflammation damnification from taking place or development increases the weight of to cause necrocytosis, thereby avoid ulcer to take place; Improve the parabiosis organizational vitality, promote to repair; Suppress hypertrophy.
Embodiment 3
National standard is controlled Mi Lingshuan (" ministry standard " the 11st 118 pages) changes system into the 8th kind new medicine and controls rotten spirit oil (changing dried Alumen into the original shape Alumen uses).
Prescription: Cortex Phellodendri 10 grams, Radix Sophorae Flavescentis 10 grams, catechu 2 grams, Borneolum Syntheticum 1 gram, Alumen 50g (manufacture and control rotten clever oily 1000ml).
Preparation method:
The first step: preparation Alumen glycerite, with embodiment 2;
Second step: extract Chinese medicine ingredients
1, Cortex Phellodendri 10 gram, Radix Sophorae Flavescentis 10 grams, catechu 2 grams cleaned, fritter, are put in the porcelain container, add DMSO and be advisable, do for the first time and extract, soak and extracted 8 hours just medical material is flooded, filter take out extracting solution 1, standby;
2, do extraction for the second time by add DMSO with quadrat method again, obtain extracting solution 2, standby;
3, do extraction for the third time by same procedure with DMSO again, obtain extracting solution 3, standby (annotating: extract the basic whole dissolvings of ingredients) through 3 times;
The 3rd step: Borneolum Syntheticum 1 gram is dissolved in second step, the 1 gained extracting solution 1;
The 4th step: preparation
1, measures 6.25% Alumen glycerite 800ml, add above-mentioned DMSO extracting solution 1 earlier, add extracting solution 2 again, add extracting solution 3 again to 1000ml.
2, stirred 15 minutes, make and control rotten clever oily 1000ml.
Control rotten clever oil and can suppress vaginal pathogenic, antiinflammatory, elimination mucosa edema, suppress to ooze out, reduce leucorrhea; Be used for the treatment of chronic cervicitis, vaginitis.Controlling rotten spirit oil has specially good effect to cervical erosion, and cervical hypertrophy, polyp are had positive effect, can make the complete obiteration of considerable part cervical polyp or dwindles, and the principle of its treatment chronic cervicitis as shown in Figure 3.The major lesions of cervical erosion is, under factor affecting such as inflammation, the squamous cell necrosis on cervical mucosa surface comes off, replaced by columnar epithelial cell, control rotten spirit oil by local anti-inflammatory mechanism, make cell dehydration eliminate cellular edema, suppress to ooze out, correct cell hypoxia and acidosis, can prevent that the continuous death of mucomembranous surface cell from coming off, thereby guarantee rotten to the corn face and lower floor's cell development maturation thereof, be finally converted into squamous cell, rotten to the corn healing, the 3rd day pathological changes began to take a turn for the better after general part was coated with and controls rotten spirit oil, and red rotten to the corn face changes light, and leucorrhea reduces, overwhelming majority patient fully recovered about 2 weeks, and cure rate and healing time are better than other drug and physiotherapy.The Chinese patent medicine of treatment cervical erosion use mainly is a suppository at present, and as BAOFUKANG SHUAN, Confort Pessaries etc., subject matter is that the quality of the pharmaceutical preparations is not high, has a strong impact on it and promotes the use of (difficult obstetrics and gynecology/Yang Dongzi chief editor: 338).To control Mi Lingshuan and change system into pharmaceutical composition of the present invention by former prescription compatibility, and overcome the shortcoming of suppository quality aspect, it is clear and bright to control rotten clever oily clean appearance, and quality and Western medicine glycerin indifference meet vagina and use hygienic requirements.
Through Jiangsu Province Center for Disease Control (CDC) and Fujian Province Center for Disease Control (CDC) result of the test, control rotten spirit oil to 2 minutes bacteriostasis rates 99.4% of representative pathogenic bacterium; The nontoxic level in the true border of acute oral toxicity animal experiment conclusion; One time vaginal mucosa irritant test conclusion belongs to nonirritant.
Embodiment 4
1, clinical case: obtain treatment at random and organize 166 routine patients, matched group 60 routine patients are the outpatient service female patients, 20～50 years old age.All case meets " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " that State Administration of Traditional Chinese Medicine issues.
2, using method: the treatment group is applied to rotten to the corn face with the rotten clever oil of controlling that makes among the embodiment 3.
(matched group: fill in the treatment of vagina depths) with Confort Pessaries.
All patients treat 1 equal every day, treat for 2 weeks.
3, effect criterion: according to " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " of State Administration of Traditional Chinese Medicine promulgation: cure: transference cure, rotten to the corn healing; Effectively: doing well,improving, wound surface dwindles gradually; Invalid: symptom is not seen improvement, the body no change.
4, therapeutic effect: 2 all clinical cure rates 85.5% are organized in treatment.Treatment group and matched group result are as shown in table 2:
The therapeutic outcome of table 2 treatment group and matched group
Embodiment 5
National standard oral cavity ulcer powder (" ministry standard " the 1st 17 pages) is changed system into the 8th kind new medicine ulcer oil.
Prescription: Alumen 50g, Borneolum Syntheticum 1 gram, Indigo Naturalis 10 grams (manufacturing ulcer oil 1000ml).
Preparation method:
With embodiment 3.
Oral cavity ulcer powder is eliminated because of dosage form falls behind, after by primary standard prescription it being changed system into pharmaceutical composition of the present invention, powder has become the dimethyl sulfoxide glycerin, the variation of matter has taken place in pharmaceutical properties, increased pharmacological action, enlarged the scope of application, ulcer oil treatment principle as shown in Figure 4.That ulcer oil has is antibiotic, antiinflammatory, inhibition edema and ooze out, prevent that blister from forming, pain relieving and the effect of promotion wound healing, can impel herpes, the equivalent damage that oozes out, festers heals rapidly, be used for the treatment of herpes simplex, herpes zoster, eczema, ulcer etc., be particularly suitable for the treatment of chronic ulcer of skin and oral ulcer, for example, 3 weeks cured two lower limb Colophoniumes of not healing in 32 years and scald 5.5 * 2.5 to 3.0 * 2.0 square centimeters the many places ulcer that stays after the skin-grafting; Cured the chronic ulcer at the leap tiger place that causes after the hand of not healing in 13 years is stabbed by Radix et Caulis Opuntiae Dillenii in one month.Ulcer oil has significant curative effect to herpes simplex and herpes zoster, is coated with outward during the early stage red and swollen pruritus of herpes simplex and can prevents blister, blister has taken place used and can stop the blister development to enlarge, and prevents incrustation, shortens the course of disease, leaves no trace after more.Can prevent the extent of disease expansion in the early stage use of herpes zoster, obvious analgesic effect is arranged.
Through Fujian Province Center for Disease Control (CDC) result of the test, ulcer oil is to 2 minutes bacteriostasis rates 97.2% of representative pathogenic bacterium; The nontoxic level in the true border of acute oral toxicity animal experiment conclusion; One time intact skin irritant test conclusion belongs to nonirritant.
Embodiment 6
1, clinical case: obtain 100 routine oral ulcer patients at random, 20～50 years old age.All case meets " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " that State Administration of Traditional Chinese Medicine issues.
2, using method: use the ulcer oil that makes among the embodiment 5 to be applied to wound surface.
3, effect criterion: according to " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " of State Administration of Traditional Chinese Medicine promulgation: cure: transference cure, wound healing; Effectively: doing well,improving, traumatic infection dwindles gradually; Invalid: symptom is not seen improvement, the body no change.
4, therapeutic effect: cure 92 examples, account for 92%, effective 8 examples account for 8%.
Embodiment 7
National standard beri-beri powder (" ministry standard " the 2nd 240 pages) is changed system into the 8th kind new medicine beriberi oil.
Prescription: Alumen 50g, the Radix Angelicae Dahuricae 15 grams, Herba Schizonepetae 10 grams (manufacturing beriberi oil 1000ml).
Preparation method: with embodiment 3 first and second, four the step.
That beriberi oil has is antibacterial, antiinflammatory, alleviate edema, suppress to ooze out, and the effect of the healing that promotes to fester is used for the treatment of erosive type tinea pedis, beriberi infection and festers etc.
Through Fujian Province Center for Disease Control (CDC) result of the test, beriberi oil is to 2 minutes bacteriostasis rates 97.4% of representative pathogenic bacterium; One time intact skin irritant test conclusion belongs to nonirritant.
Embodiment 8
1, clinical case: obtain at random, be outpatient service beriberi patient, at 20～50 years old age, 58 examples are organized in treatment; All case meets " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " that State Administration of Traditional Chinese Medicine issues.
2, using method: use the beriberi oil that makes among the embodiment 7 to be applied to infected position.
3, effect criterion: according to " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " of State Administration of Traditional Chinese Medicine promulgation: cure: transference cure, wound healing; Effectively: doing well,improving, traumatic infection dwindles gradually; Invalid: symptom is not seen improvement, the body no change.
4, therapeutic effect: cure 45 examples, account for 75.9%, effective 13 examples account for 24.1%.
Embodiment 9
With reference to national standard SHAOSHANGLING DING (" Chinese pharmacopoeia 2000 version 562 pages) prescription, on former prescription compatibility basis, increase Alumen, produce the 6th kind new medicine burn spirit oil.
Prescription: Borneolum Syntheticum 1 gram, Rhizoma Polygoni Cuspidati 15 grams, Cortex Phellodendri 10 grams, Alumen 50g (manufacturing the clever oily 1000ml of burn)
Preparation method: with embodiment 3.
The clever oil nature non-greasy, moist of burning, with after need not remove and change dressings, easy to use, the treatment principle is as follows:
1, suppresses to kill pathogenic bacterium, prevention infection;
2, the clever oil of burn has powerful edema, the inhibition transudation of alleviating, and is particularly suitable in early days at burn;
3, Alumen solidifiable, the precipitating proteins in the preparation, astriction is strong, and can prevent incrustation to form, and fundamentally avoids infecting under the crust;
4, burn spirit oil is glycerin preparation, can keep the wound surface moist environment that suits, and both being different from the vegetable oil agent influences moisture evaporation, also is different from aqueous solution drying easily.Moist environment has the effect (clinical burns unit/Pueraria lobota rope moral 2006:252-257) of quickening wound healing and improving healing quality to burn wound's particular importance
The clever oily non-evident effect of burning can be used for treating I-III degree burn and scald, is particularly useful for severe empyrosis wound surface nursing for treating, uses when being particularly suitable for the wound surface exposure method.
Through Fujian Province Center for Disease Control (CDC) result of the test, burn spirit oil is to 2 minutes bacteriostasis rates 96.5% of representative pathogenic bacterium; The nontoxic level in the true border of acute oral toxicity animal experiment conclusion; One time intact skin irritant test conclusion belongs to nonirritant.
Embodiment 10
1, clinical case: obtain 30 examples at random, be outpatient service burn and scald patient, at 20～50 years old age, 10 examples are small size severe burn and scald, 20 examples are light moderate burn and scald, and all case meets " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " that State Administration of Traditional Chinese Medicine issues.
2, using method: use the burn spirit oil that makes among the embodiment 9 to be applied to the burn and scald position.
3, effect criterion: according to " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " of State Administration of Traditional Chinese Medicine promulgation: cure: transference cure, wound healing; Effectively: doing well,improving, traumatic infection dwindles gradually; Invalid: symptom is not seen improvement, the body no change.
4, therapeutic effect: 10 severe burn and scald are cured 7 examples, cure rate 70%, effective 3 examples; The light moderate burn and scald of 20 examples is all cured cure rate 100%.
Embodiment 11
(manufacturing hibitane Alumen glycerin liquid 1000ml)
Prescription: hibitane 1 gram, Alumen 50 grams, glycerol 800ml, DMSO200ml (hibitane working concentration 1: 1000) preparation method:
The first step: preparation Alumen glycerite, with embodiment 2.
Second step: take by weighing hibitane 1 gram, be dissolved among the 200mlDMSO, standby.
The 3rd step: measure 6.25% Alumen glycerite 800ml, 200ml hibitane DMSO solution is added wherein, stir, make the hibitane working concentration and be 1: 1000 hibitane Alumen glycerin liquid.
Hibitane is the biguanides cationic surfactant, it is the particularly the most frequently used disinfectant of gynecological of surgery, stronger antibacterial, bactericidal action are arranged, killing action to gram-positive bacterium and gram negative bacteria is better than bromo geramine, be made into tablet, suppository, emulsifiable paste, chewing gum, patch etc. in recent years and be used for the treatment of oral ulcer, mixed hemorrhoids, burn, vaginal infection or cervical erosion, and be used for open wound and surgical wound nursing etc. (Meikang, the clinical drug information reference .2008/ Sichuan medicine software study 2008:1556 of development corporation, Ltd.).Hibitane and Alumen compatibility are made into pharmaceutical composition of the present invention, can add powerful antiinflammatory action and astriction on the basis of antibacterial action, thereby improve curative effect.
Fujian Province Center for Disease Control (CDC) result of the test, hibitane Alumen glycerin liquid is to 2 minutes bacteriostasis rates 100% of representative pathogenic bacterium; One time vaginal mucosa irritant test conclusion belongs to nonirritant.
Embodiment 12
1, clinical case: obtain 50 routine patients at random, be the outpatient service female patients, 20～50 years old age, wherein bacterial vaginitis 30 examples; Trichomonal vaginitis 20 examples; All case meets " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " that State Administration of Traditional Chinese Medicine issues.
2, using method: be applied to intravaginal with the hibitane Alumen glycerin liquid that makes among the embodiment 11.
3, effect criterion: according to " traditional Chinese medical science medical diagnosis on disease criterion of therapeutical effect " of State Administration of Traditional Chinese Medicine promulgation: cure: transference cure, wound healing; Effectively: doing well,improving, traumatic infection dwindles gradually; Invalid: symptom is not seen improvement, the body no change.
4, therapeutic effect: 50 routine vaginitiss are cured 48 examples, cure rate 96%, and effective 2 examples accounted for for 4% (illustrate: trichomonal vaginitis cooperates oral metronidazole).
The foregoing description is a preferred implementation of the present invention; but embodiments of the present invention are not restricted to the described embodiments; other any do not deviate from change, the modification done under spirit of the present invention and the principle, substitutes, combination, simplify; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (10)
1. local anti-inflammatory external medicinal composition that uses glycerol DMSO mixed solvent is characterized in that: what comprise the medicine of Alumen, anti-inflammatory effective amount and be used to dissolve Alumen and described medicine is the mixed solvent that 1: 0.5～5 dimethyl sulfoxide and glycerol are formed by volume ratio.
2. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 1, it is characterized in that: described medicine is medicine monomer, pharmaceutical composition or the extract that at least a Chinese medicine is originated.
3. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 1, it is characterized in that: described medicine is Western medicine monomer or its compositions.
4. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in claim 2 or 3, it is characterized in that: preferably using volume ratio is 1: 4 the dimethyl sulfoxide and the mixed solvent of glycerol composition.
5. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 4, it is characterized in that: the w/v of Alumen and glycerol/DMSO mixed solvent is 1～10g/100ml.
6. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 5, it is characterized in that: described medicine is that weight ratio is the DMSO extract and the Borneolum Syntheticum of 1: 0.5～1.5: 0.1～0.3 Cortex Phellodendri, Radix Sophorae Flavescentis, catechu, the w/v of employed Cortex Phellodendri medical material or Radix Sophorae Flavescentis medical material and glycerol/DMSO mixed solvent is 5g/1000ml～15g/1000ml, and the w/v of Borneolum Syntheticum and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
7. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 5, it is characterized in that: described medicine is the DMSO extract and the Borneolum Syntheticum of Indigo Naturalis, the w/v of employed Indigo Naturalis medical material and glycerol/DMSO mixed solvent is 5g/1000ml～15g/1000ml, and the w/v of Borneolum Syntheticum and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
8. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 5, it is characterized in that: described medicine is that weight ratio is the DMSO extract of 1: 1～2 Herba Schizonepetaes and the Radix Angelicae Dahuricae, and the w/v of employed angelica root and glycerol/DMSO mixed solvent is 10g/1000ml～20g/1000ml.
9. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 5, it is characterized in that: described medicine is that weight ratio is 1: 1～2 the Cortex Phellodendri and the DMSO extract and the Borneolum Syntheticum of Rhizoma Polygoni Cuspidati, the w/v of employed Rhizoma Polygoni Cuspidati medical material and glycerol/DMSO mixed solvent is 10g/1000ml～20g/1000ml, and the w/v of Borneolum Syntheticum and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
10. according to the local anti-inflammatory external medicinal composition of the use glycerol DMSO mixed solvent described in the claim 5, it is characterized in that: described medicine is a hibitane, and the w/v of hibitane and glycerol/DMSO mixed solvent is 0.5g/1000ml～1.5g/1000ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101489479A CN101874809A (en) | 2009-04-30 | 2010-04-16 | Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910302034 | 2009-04-30 | ||
| CN200910302034.5 | 2009-04-30 | ||
| CN2010101489479A CN101874809A (en) | 2009-04-30 | 2010-04-16 | Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101874809A true CN101874809A (en) | 2010-11-03 |
Family
ID=43017555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101489479A Pending CN101874809A (en) | 2009-04-30 | 2010-04-16 | Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101874809A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599231A (en) * | 2013-11-25 | 2014-02-26 | 来临 | Traditional Chinese medicinal liquid for preventing and treating wound infection and preparation method thereof |
| CN110339313A (en) * | 2019-08-12 | 2019-10-18 | 南京依美生物科技有限公司 | A kind of gynecological gel preparation and preparation method thereof for treating cervical polyp |
| WO2019226699A1 (en) * | 2018-05-21 | 2019-11-28 | Veloce Biopharma Llc | Novel agents for the treatment of skin diseases |
| CN111568944A (en) * | 2020-04-03 | 2020-08-25 | 湖州市中医院 | Traditional Chinese medicine preparation for treating colpitis mycotica and preparation method thereof |
| US10864240B2 (en) | 2016-05-30 | 2020-12-15 | Yuanqiao Fu | Pharmaceutical composition for treating skin wounds and a method of treating skin wounds using thereof |
| CN113208107A (en) * | 2021-04-01 | 2021-08-06 | 王允太 | Health-care pomelo oil and preparation method thereof |
| CN115463049A (en) * | 2022-08-29 | 2022-12-13 | 江苏知原药业股份有限公司 | Gargle formula, production process and production equipment thereof |
-
2010
- 2010-04-16 CN CN2010101489479A patent/CN101874809A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599231A (en) * | 2013-11-25 | 2014-02-26 | 来临 | Traditional Chinese medicinal liquid for preventing and treating wound infection and preparation method thereof |
| CN103599231B (en) * | 2013-11-25 | 2015-12-02 | 来临 | Traditional Chinese medicine liquid for preventing and treating wound infection and preparation method thereof |
| US10864240B2 (en) | 2016-05-30 | 2020-12-15 | Yuanqiao Fu | Pharmaceutical composition for treating skin wounds and a method of treating skin wounds using thereof |
| CN113413375A (en) * | 2016-05-30 | 2021-09-21 | 傅远桥 | External-use medicine composition for treating various wound surfaces of skin and preparation method thereof |
| US11571452B2 (en) | 2016-05-30 | 2023-02-07 | Yuanqiao Fu | Method of treating a skin wound with a liquid-state topical pharmaceutical composition |
| WO2019226699A1 (en) * | 2018-05-21 | 2019-11-28 | Veloce Biopharma Llc | Novel agents for the treatment of skin diseases |
| CN110339313A (en) * | 2019-08-12 | 2019-10-18 | 南京依美生物科技有限公司 | A kind of gynecological gel preparation and preparation method thereof for treating cervical polyp |
| CN111568944A (en) * | 2020-04-03 | 2020-08-25 | 湖州市中医院 | Traditional Chinese medicine preparation for treating colpitis mycotica and preparation method thereof |
| CN113208107A (en) * | 2021-04-01 | 2021-08-06 | 王允太 | Health-care pomelo oil and preparation method thereof |
| CN115463049A (en) * | 2022-08-29 | 2022-12-13 | 江苏知原药业股份有限公司 | Gargle formula, production process and production equipment thereof |
| CN115463049B (en) * | 2022-08-29 | 2023-10-20 | 江苏知原药业股份有限公司 | Gargle formula and production process and production equipment thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406761B (en) | Traditional Chinese medicine oil for treating burn, scald or acute and chronic ulcer sore surface and preparation method thereof | |
| CN101209267B (en) | Use of nocardia rubracell wall skeleton in preparing medicament for treating skin damage and pyogenic infection | |
| CN101874809A (en) | Local anti-inflammatory external medicinal composition using glycerol DMSO mixed solvent | |
| CN103316261B (en) | Medical antibacterial liquid and preparation method thereof | |
| CN103272153A (en) | Antibacterial gel and preparation method thereof | |
| CN103316262B (en) | A kind of gynecological external antibacterial liquid and preparation method thereof | |
| WO2011023013A1 (en) | Medicine for dissolving and eliminating wart and excrescence consisting of protein and its uses | |
| CN101703651B (en) | Medicament for treating diabetic gangrene | |
| CN103893640B (en) | A kind of chitosan infant bio-medical antimicrobial fluid and preparation method thereof | |
| CN1903289A (en) | Gel for treating hemorrhoidal anus and rectum diseases, and its prepn. method | |
| CN101433617B (en) | Disinfecting paste for dissolving wart and eliminating wart | |
| CN104888058A (en) | Antibacterial and anti-inflammation external preparation and method for preparing same | |
| CN102106882B (en) | Natural compound medicine for treating acnes and scars | |
| CN103520262B (en) | A kind of lipid soluble gynecological gel | |
| CN106377602A (en) | Dendrobium officinale composite disinfection powder, and preparation method and application method thereof | |
| CN1326546C (en) | Pure Chinese medicinal preparation for external treating burn and scald | |
| CN103877452B (en) | A kind of chitosan vaginal washing fluid and preparation method thereof | |
| CN108938703A (en) | The gynecological gel of quick antibacterial | |
| CN104043089A (en) | Medical biological dressing suppository for treating hemorrhoid | |
| CN103908600A (en) | Externally-applied medicine for treating rheumatoid arthritis damp-heat blockage symptom as well as preparation method and administration method thereof | |
| CN115444912A (en) | Composition for treating acne and preparation method thereof | |
| CN103007034A (en) | Traditional Chinese medicine composition used for treatment of residual second-degree burn wound, and preparation method thereof | |
| CN100355437C (en) | Medicine for treating scald and burn and preparing method | |
| CN108324721B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN101647954A (en) | Traditional Chinese medicine for treating cervicitis and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101103 |